Podcasts

Episode 175: Reframing Your Thoughts with Mindfulness

Mindfulness is the intentional act of paying attention to one’s body, sensations, thoughts, feelings, or surroundings in the present moment, without judgment. Practicing mindfulness can give a sense of calm, help manage pain, reduce stress, and improve clarity and mental well-being. In being aware of and calmly accepting feelings, thoughts, and bodily sensations in a non-judgmental way, individuals can reshape their thoughts and expectations into something more manageable. For people with Parkinson’s disease (PD), mindfulness is particularly good for reducing anxiety and depression, as well as coping with daily stressors.

In this episode, Crista Ellis, Senior Community Program Manager with the Parkinson’s Foundation and a certified yoga and meditation educator, describes what mindfulness is, how easy it is to practice in a short amount of time, and how it can benefit people with PD. She also leads us through a brief mindfulness practice for listeners to participate in.

Released: January 28, 2025

Raise Awareness

Empowering Black and African American Communities with Parkinson’s: Education and Advocacy in Action

Large group of people posing for a picture.

Black and African American people living with Parkinson’s disease (PD) often face significant health disparities, limiting access care. To bridge this gap, the Parkinson’s Foundation launched Parkinson’s Journey in Color: Advancing Research and Care in Your Community — events tailored to meet the unique needs and experiences of local Black and African American PD communities. Each event offered in-person genetic testing at no cost through the Foundation’s landmark genetics study, PD GENEration: Mapping the Future of Parkinson’s Disease.  

Five Women posing for a picture

A Collaborative Approach Rooted in Community 

Part of our mission is to amplify the voices of those living with Parkinson’s. Parkinson’s Journey in Color was designed through a collaboration with Parkinson’s Foundation research advocates and staff. Research advocates are volunteers who complete Parkinson’s Foundation training to help ensure PD research is more efficient and effective. 

When it came to Parkinson’s Journey in Color, research advocates helped guide every aspect of the events — from shaping topics to selecting central location. They also identified and worked with community partners to promote and participate in the events, ensuring that the program resonated with local audiences. 

“Working alongside advocates who are all people in the PD community, we recognized their unparalleled understanding of their communities and cultural values, allowing us to create an inclusive and empowering event that reaches more people with Parkinson’s,” said Evelyn Stevens, Parkinson's Foundation senior director of community engagement.  

The research advocates who helped shape these events were trained in collaboration with Morehouse School of Medicine in September 2023 (learn more in this article). These advocates, who are people living with Parkinson’s and care partners who identify as Black or African American, brought their experiences, insights and cultural expertise to the forefront of Parkinson’s Journey in Color events. 

Women speaking to an audience at event

Tailored Programming to Address Community Needs 

The Parkinson’s Foundation hosted three Parkinson’s Journey in Color events in 2024.  

  1. Atlanta, GA: Our March 9 event was held alongside Morehouse School of Medicine and Emory Brain Health Center. Fifty-five people attended, with most saying it was their first Parkinson’s Foundation event. Ten people completed PD GENEration testing at the event. 

  2. Charlotte, NC: Our September 14 event hosted 51 attendees and was held at The Park Church, a recommendation by a research advocate that allowed the Foundation to strengthen its connections with faith-based leaders and trusted sources within the Black and African American community. Attendees shared their experiences with participating in research, including PD GENEration. The event featured a “Connections to Care” table that provided resources for local neurologists and an opportunity to meet with local healthcare professionals experienced in PD.  

  3. Chicago, IL: Our November 16 event hosted 45 attendees and was held at the University of Illinois Chicago. Part of its focus was on research and care, with four PD GENEration sites in attendance that provided attendees with information and resources for care and PD GENEration testing. Participants also had the opportunity to meet with movement disorders specialists from Northwestern University, Rush University (both Parkinson’s Foundation Centers of Excellence) alongside University of Chicago and University of Illinois at Chicago.  

“Each of our journeys are quite colorful. In Charlotte, one of our church leaders shared with me, ‘who knew so many African American people have a PD diagnosis?’ I shared there are more as well. That's what this advocacy is all about,” said Lisa Fletcher, a care partner and the Parkinson’s Foundation research advocate who suggested partnering with a local church.  

Large group of people having fun at an event

Openly Discussing Critical Parkinson’s Topics 

While each event featured a customized list of topics, all shared essential PD information including:  

  • Parkinson’s Disease 101: A session led by a movement disorders specialist (a neurologist experienced in PD) who reflected the community’s identity, fostering relatability and trust. 

  • The Importance of Research: A candid discussion that acknowledged the historical mistreatment of the Black and African American community in research while highlighting progress and current safeguards to rebuild trust. 

  • Introduction to PD GENEration: Information on genetic testing and counseling opportunities to empower participants with knowledge and tools for proactive care. 

  • Lived Experience Sharing: Stories and insights from local people living with Parkinson’s and their care partners, providing inspiration and a sense of shared understanding. 

The Black Community & Parkinson’s  

Group of people speaking at an event

Black and African American people diagnosed with Parkinson’s have unique experiences and needs when it comes to living with PD. Research shows that Black people with PD are diagnosed at a later disease stage than white people. 

Research also shows that Black people are less likely to be diagnosed compared to other racial and ethnic groups. This is in large part due to Black communities being historically excluded in the healthcare system and research studies. Because of this, the full impact of the disease within the community is still unknown. 

The Parkinson’s Foundation works to bring awareness to these disparities and more so we can make health care more accessible across the PD community, through reaching and supporting populations of focus, including those who identify as Black and African American. Explore our resources and information that can help you find a specialist, build a care team and find local resources, like support groups and exercise classes. 

Learn More 

Building a Stronger Future Together 

“Parkinson’s Journey in Color represents more than just an education and care event— it is a testament to the power of community-driven solutions and advocacy,” said Evelyn. “Through centering the voices of Black and African American individuals living with Parkinson’s, we are fostering a more inclusive and equitable approach to care, research and support.” 

Through initiatives like this and designing new ones that reach more populations of focus, the Parkinson’s Foundation aims to build stronger connections within local communities, address disparities in care and empower individuals with the knowledge and resources they need to thrive.  

Find ways to get involved with the Parkinson’s community that works for you — from attending local Parkinson’s Foundation events to joining a research study.   

Educational Events

Learn More. Live Better. Parkinson's Midwest Chapter Symposium.

Virtual ( Zoom )
12:00 pm to 4:00 pm CDT
Free
Learn More. Live Better. Parkinson's Symposium banner

In-person check-in begins at 12 p.m. and the program starts at 1:00 p.m. A complimentary boxed lunch will be provided. Please call Jessica at (312) 762-5706 if you have any dietary requirements.

Living with Parkinson's can be challenging, but there are many things you can do to maintain and improve your quality of life. This program will provide you with information to help you find the balance between a proactive approach and wondering what lies ahead. We will cover common Parkinson's disease (PD) medications, their benefits, potential side effects, and the need for adjustments over time. We will also emphasize the importance of a well-rounded care plan that includes exercise and social engagement to combat isolation. Together, these factors can greatly improve the quality of life for those living with PD.

Speakers

Danny Bega, MD, MSCI
Northwestern Medicine Parkinson's Disease & Movement Disorders Center, A Parkinson's Foundation Center of Excellence

Katie Fagan, MSW, LCSW, CDP
Northwestern Medicine Parkinson's Disease & Movement Disorders Center, A Parkinson's Foundation Center of Excellence

Adam Burns, PT, DPT, NCS
Allied Health Supervisor, Burr Ridge, Outpatient Center
Senior I Physical Therapist
APTA Board Certified Neurologic Clinical Specialist
Shirley Ryan AbilityLab

There is no charge to attend, but registration is required. This program is open to people with Parkinson's, their families, friends, and the community.

Sponsor

Upcoming Events

Educational Events

Thinking & Memory Changes

Many people with Parkinson's disease experience thinking changes such as trouble focusing, multitasking, or finding the right words. Learn more about these changes as well as tips to help with daily tasks, treatment options and resources for emotional and social support.

Livonia, MI
Fact Sheets

La genética y el Parkinson

En la enfermedad de Parkinson (EP) se pierden las células cerebrales que producen dopamina, una sustancia química que favorece el movimiento, el estado de ánimo y otras funciones.

Aunque la causa de esta pérdida celular no se conoce del todo, se cree que influyen la genética, el medio ambiente y el estilo de vida, que varían en cada persona. Estudiar la genética es clave para mejorar el tratamiento y acercarnos a una cura.

Datos relevantes

  • Entre un 12-15% de las personas con la EP tienen un vínculo genético
  • Los factores genéticos pueden aumentar el riesgo de Parkinson.
  • La participación en estudios genéticos ayuda a los científicos a entender las causas y la progresión del Parkinson.

Pruebas genéticas:

  • Apoyan decisions informadas sobre la salud
  • Le ayudan a determinar si puede participar en ensayos clínicos relacionados con sus genes
  • Podrían tener costos si se realizan fuera de un estudio

Estudios genéticos:

  • Algunos ofrecen pruebas genéticas y consejería genética gratuitas
  • Los resultados se utilizan para impulsar la investigación
  • Pueden conducir a terapias específicas adaptadas a sus genes

Entendiendo la genética

La genética es el estudio de cómo rasgos como el color de los ojos y la estatura pasan de padres a hijos. En el centro de este proceso está el ADN, que es como un recetario con unos 23,000 genes o "recetas" que nos hacen quienes somos. Cada gen da instrucciones para producir proteínas que construyen y reparan el cuerpo, ayudan al sistema inmunitario y cumplen muchas otras funciones. 

Los genes pueden tener cambios llamados variantes. La mayoría de las variantes no tienen ningún efecto. Algunas determinan rasgos únicos, como los ojos marrones. Otras afectan cómo funcionan las proteínas y pueden aumentar la probabilidad de problemas de salud. Aunque la genética juega un papel importante, la salud depende de una combinación de genes, estilo de vida y medio ambiente.

Cómo influye la genética en el Parkinson

Los cambios en genes específicos, como LRRK2, GBA y SNCA, pueden aumentar el riesgo de desarrollar la EP o influir en cómo evolucionan los síntomas en personas ya diagnosticadas.

Los investigadores están estudiando cómo varían estos cambios genéticos entre diferentes grupos para entender por qué el Parkinson es más común en ciertas comunidades. Comprender estas diferencias genéticas puede darnos pistas sobre por qué la EP varía de una persona a otra.

Pruebas genéticas

Las pruebas genéticas pueden ayudar a identificar el riesgo de desarrollar la EP o apoyar una atención más personalizada.

  • Las pruebas suelen consistir en una muestra de sangre o saliva para detectar cambios en el ADN o las proteínas.
  • Algunas pruebas se hacen en casa y se envían por correo, mientras que para otras hay que ir a una clínica.
  • Los costos y la cobertura de seguros pueden variar.

Antes de la prueba, hable con su médico acerca de qué implica y lo que los resultados pueden significar para usted y su familia. Un asesor genético puede ayudarle a entender el proceso y a planificar los próximos pasos.

Estudio genético de la Parkinson’s Foundation

PD GENEration: Impulsado por la Parkinson’s Foundation, es un estudio global que ofrece pruebas y consejería genéticas sin costo a las personas diagnosticadas con la EP. Los participantes reciben sus resultados y pueden elegir que se les contacte si surge nueva información. Los datos genéticos se resguardan sin información personal y se utilizan en todo el mundo para mejorar la comprensión de los riesgos y el tratamiento de la EP.

Puede inscribirse en línea y proporcionar una muestra de sangre con un sencillo kit casero o en un centro de investigación. Al participar, ayuda a impulsar la investigación y a entender su propia genética. 

Impulsando la atención personalizada

Los estudios exploran tratamientos para personas con cambios en genes específicos, como LRRK2, GBA o SNCA. Enfocarse en estos genes puede llevar a terapias más personalizadas. Conocer su perfil genético ayuda a saber si reúne los requisitos para estos estudios.

Consejos sobre pruebas e investigación genéticas

  • Infórmese. Contacte a nuestra Línea de Ayuda si tiene preguntas sobre las pruebas genéticas o el estudio PD GENEration.
  • Sepa qué esperar. La mayoría de las pruebas no identifica un cambio genético relacionado con la EP, pero cada resultado ayuda a la investigación.
  • Manténgase al día. Siga las investigaciones genéticas en curso. Estudios como PD GENEration siguen aportando información importante sobre la EP.
Educational Events

Let's Talk About It

1:00 pm to 3:00 pm EST
Free

Check-in starts at 12 p.m. and the program starts at 1 p.m. 

There are many non-motor challenges associated with Parkinson's disease that may not always be easy to discuss. With a focus on sleep issues and falls, this program will provide strategies for coping and talking about it with healthcare providers or loved ones. We will hear about how Parkinson's affects sleep quality and learn about the neurobiology behind fall risk.

Speakers

Mark Garwood, MD 
Assistant Professor of Neurology, Michigan Medicine

Vikas Kotagal, MD, MS
Associate Professor of Neurology, Michigan Medicine

Katie Afton
Coordinator of Rock Steady Boxing at TITLE A2

There is no charge to attend, but registration is required. This program is open to people with Parkinson's, their families, friends, and the community.

This program is done in partnership with Michigan Medicine and registration information will be shared with them. 

Supernus
Acadia More to Parkinson's

Upcoming Events

Educational Events

Thinking & Memory Changes

Many people with Parkinson's disease experience thinking changes such as trouble focusing, multitasking, or finding the right words. Learn more about these changes as well as tips to help with daily tasks, treatment options and resources for emotional and social support.

Livonia, MI
Educational Events

Expert Briefing: Managing Nighttime Interruptions in Parkinson's Disease

Virtual ( Zoom )
1:00 pm to 2:00 pm EST
FREE
Husband and wife lookin at a tablet while on their porch

Wellness Wednesday: Expert Briefing Series

Sleep disturbances are a common and often challenging symptom of Parkinson’s disease (PD). This program explores three prevalent nighttime interruptions—Restless Legs Syndrome (RLS), REM Sleep Behavior Disorder (RBD), and insomnia—that can affect individuals with PD and their care partners. This session will provide an in-depth look at the causes, symptoms, and practical management strategies for these sleep disorders.

Speaker

Roneil G. Malkani, MD
Associate Professor, Northwestern University Feinberg School of Medicine
Neurologist, Northwestern Memorial Hospital
Specializing in Sleep Medicine and Movement Disorders

There is no charge to attend, but registration is required. This program is open to people with Parkinson's, their family, friends, and the community.

PD Health @ Home is presented by the Light of Day Foundation, whose generosity has made this programming possible.

Light of Day

This is a virtual program, taking place live, using the online Zoom platform. Instructions on joining the webinar are provided after registering.

Upcoming Events

Educational Events

Thinking & Memory Changes

Many people with Parkinson's disease experience thinking changes such as trouble focusing, multitasking, or finding the right words. Learn more about these changes as well as tips to help with daily tasks, treatment options and resources for emotional and social support.

Livonia, MI
Educational Events

Parkinson's 101

Virtual ( Zoom )
1:00 pm to 2:00 pm EST
FREE
Husband and wife lookin at a tablet while on their porch

This program offers an introduction and basic overview of Parkinson’s disease (PD). PD varies from person to person and changes over time. Discover its causes, common symptoms, available treatments and effective strategies for managing them. Learn practical daily living tips to empower you to take charge of your health and to navigate the challenges of living with PD.

Speaker

Aditya Vikram Boddu, MD
Assistant Professor
Department of Neurology
Division of Movement Disorders
University of Arkansas for Medical Sciences

There is no charge to attend, but registration is required. This program is open to people with Parkinson's, their family, friends, and the community.

We want to thank this webinar's sponsor, BioGen, for supporting our mission. 

Sponsor

Biogen Logo

PD Health @ Home is presented by the Light of Day Foundation, whose generosity has made this programming possible.

Light of Day

This is a virtual program, taking place live, using the online Zoom platform. Instructions on joining the webinar are provided after registering.

Upcoming Events

Educational Events

Thinking & Memory Changes

Many people with Parkinson's disease experience thinking changes such as trouble focusing, multitasking, or finding the right words. Learn more about these changes as well as tips to help with daily tasks, treatment options and resources for emotional and social support.

Livonia, MI
Educational Events

Navigating Advancing Needs

11:00 am to 2:30 pm EST
FREE
PF_Home_Bedroom_0150-3.jpg

Navigating Parkinson’s disease involves looking ahead, learning and adjusting as symptoms and needs change. This program addresses some of the challenges of advancing PD and explores strategies to prepare for the future, including how to evolve your care plans and treatments throughout progression so you can live your best life with PD now.

Speakers

Nami Shah, MD
Department of Neurology, Movement Disorders
University of Rochester

Megan Hotchkiss, PT, DPT
Director of Clinical Education/Associate Professor
Ithaca College

Gold Sponsor

Upcoming Events

Educational Events

Thinking & Memory Changes

Many people with Parkinson's disease experience thinking changes such as trouble focusing, multitasking, or finding the right words. Learn more about these changes as well as tips to help with daily tasks, treatment options and resources for emotional and social support.

Livonia, MI
Science News

Update: New Study Finds Drugs like Ozempic Ineffective for Parkinson’s Treatment

Parkinson's Foundation Science News blogs

Update: February 21, 2025

This February, a new study published in the medical journal The Lancet has cast substantial doubt on the potential effectiveness of the diabetes drug class GLP-1 receptor agonists on treating Parkinson’s disease (PD).

A phase 3 clinical trial evaluated the GLP-1 receptor agonist called Exenatide. The study,  consisting of 194 participants followed over two years, found that daily use of Exenatide did not provide any significant improvement for Parkinson’s symptoms compared to the placebo. This lack of improvement was consistent across age groups, sexes and PD stages. The researchers also performed pre- and post-study CT brain scans on select participants, finding that Exenatide did not impact dopamine activity in the PD-relevant regions of the brain.

These results suggest that the current GLP-1 receptor agonists medications are not effective as Parkinson’s disease-modifying treatments. As scientists learn more about the GLP-1 biological pathway and how it affects dopaminergic neuron health, there will likely be future development and trials of new GLP-1 drugs specifically designed for Parkinson’s.

January Article

Parkinson's disease is a neurodegenerative disorder where dopamine-producing cells in the brain slowly break down over time. This loss of dopamine leads to a variety of movement symptoms, including tremors, stiffness, slow movement and difficulty with balance. While current treatments can help manage many PD symptoms, they do not address what causes the disease and therefore cannot prevent its progression.  

Emerging research suggests a potential link between the brain's decreased sensitivity to the hormone insulin and the progression of Parkinson's. This observation has prompted researchers to investigate whether anti-diabetic medications that help manage insulin levels could potentially slow the progression of Parkinson's. 

Person holding ozempic injection pen

Trending drugs Ozempic and Wegovy belong to a class of diabetes medications called GLP-1 receptor agonists, which along with certain other diabetes medications have shown potential in reducing the risk of developing Parkinson’s in people with diabetes. These drugs mimic the action of a natural hormone that regulates blood sugar levels. 

However, it is not known whether GLP-1 receptor agonists drugs may benefit people with Parkinson’s who don’t have diabetes. 

A recent clinical trial, published in the New England Journal of Medicine, tested whether a GLP-1 agonist called lixisenatide could be a new treatment approach for people in the early stages of Parkinson's. The study showed that lixisenatide, which was approved by the FDA to help diabetics control blood sugar in 2016, helped movement symptoms in people with PD and may slow the progression of Parkinson’s.  

As part of this study, a mouse model of Parkinson's demonstrated that lixisenatide improved movement issues and preserved brain cells, suggesting GLP-1 agonists may treat the underlying causes of PD.  

Additionally, lixisenatide is not the only GLP-1 receptor agonist with potential therapeutic applications for Parkinson's — at least six other similar medications are currently being evaluated as a potential PD treatment. However, compared with liraglutide and semaglutide (such as Wegovy), lixisenatide appears to be more effective in crossing the blood brain barrier. 

Study Results

The new study — a phase 2 clinical trial — enrolled 156 people with Parkinson’s, who were randomly assigned to receive lixisenatide or a placebo. The participants were diagnosed with Parkinson’s within the prior three years and were taking dopaminergic medications, such as levodopa, and continued to do so through the trial. For each participant, researchers assessed symptoms before treatment and after 12 months with daily injection of either placebo or lixisenatide. 

After 12 months of treatment, people who received lixisenatide showed better results with their movement symptoms compared to those who received a placebo. While the movement symptoms of the lixisenatide group did not change compared to the start of the trial, the placebo group experienced worsening of their symptoms.  

After 12 months of taking lixisenatide or a placebo, participants underwent two months without any treatment, with symptoms reassessed. The lixisenatide group showed better movement symptoms compared to the control group after two months, suggesting that lixisenatide may have a positive impact on disease progression.  

Of note, those who received lixisenatide had more gastrointestinal side effects — 46% of participants on lixisenatide had nausea and 13% experienced vomiting. About a third of participants (28 people) receiving lixisenatide opted for a lower dose during the study due to side effects. 

Highlights 

  • The study enrolled 156 people with Parkinson’s, who were randomly assigned to receive either a once daily injection of lixisenatide (a GLP-1 agonist) or a placebo. 

  • After a year of treatment, people who received lixisenatide showed better outcomes in their movement symptoms compared to those who received a placebo. 

  • Lixisenatide caused many participants to have gastrointestinal side effects — 46% of participants had nausea and 13% experienced vomiting. 

What does this mean for GLP-1 drugs and Parkinson’s? 

This study may mean that certain GLP-1 agonists could be beneficial in reducing certain Parkinson’s symptoms. These promising results will inspire more research on the long-term impacts of lixisenatide on PD progression.  

This study had a small sample size and only assessed the drug in those who were newly diagnosed (diagnosed within three years). Larger studies, with significantly more participants living with wider ranges of PD stages, are needed before we can make the connection between GLP-1 agonists and symptom management or disease progression.  

Lastly, there are many GLP-1 agonists currently being researched for PD treatment, and other similar drugs have shown less promising results compared to lixisenatide. More research is needed to understand the differences between various GLP-1 agonists on PD symptoms.  

What do these findings mean to the people with PD right now? 

Currently, GLP-1 agonists are only approved for treating diabetes and obesity. People with Parkinson’s who also have diabetes and obesity should talk to their doctor before starting a GLP-1 agonist. There is currently insufficient evidence to support the use of GLP-1 agonists like lixisenatide as a treatment for people with Parkinson’s who do not have diabetes or obesity.  

Additionally, the weight loss associated with GLP-1 agonists may be a problem for the many people with Parkinson’s who experience unintended weight loss through the course of the disease.  

Of note, lixisenatide is no longer available in the U.S.  

Learn More

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about PD and the topics in this article through our below resources, or by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) for answers to your Parkinson’s questions. 

Raise Awareness

Herramientas para abordar las alteraciones del pensamiento y la memoria en la EP

Women sitting on couch in pain

A medida que envejecemos, nuestra habilidad de pensamiento cambia. Los cambios cognitivos también pueden aparecer en la enfermedad de Parkinson (EP), incluyendo pensamiento más lento, olvidos, falta de concentración y, en ocasiones, pérdida de memoria. En este artículo, aprenda estrategias prácticas para reducir el riesgo de alteraciones del pensamiento y mejorar la salud cognitiva y descubra las terapias disponibles para los trastornos cognitivos. 

El siguiente artículo se basa en una Charla con expertos de la Parkinson’s Foundation (Expert Briefings) acerca de las alteraciones del pensamiento y la memoria en la EP, con el Dr. Gregory Pontone, médico con maestría en ciencias de la salud, de la Facultad de Medicina de la University of Florida, un Centro de Excelencia de la Parkinson’s Foundation. 

Envejecimiento y cognición 

Algunos procesos del pensamiento se conservan bien a medida que envejecemos, incluyendo:  

  • El vocabulario y los conocimientos generales. 

  • Las competencias lingüísticas. 

  • Recordar cómo se hacen las cosas, como andar en bicicleta o cocinar pasta (memoria procedimental), el nombre del presidente o de un vecino (memoria semántica). 

  • La capacidad de comprender lo que vemos.  

Los cambios en cualquiera de estas capacidades antes de los 70 años podrían estar relacionados con la EP u otra enfermedad asociada al envejecimiento. A medida que una persona se acerca a los 70 años, la edad o el Parkinson pueden influir en: 

  • La capacidad de retener información a corto plazo mientras se concentra en otra tarea (memoria funcional). 

  • Planificar, organizar y realizar tareas (función ejecutiva). 

  • Atención focalizada y dividida. 

  • La rapidez con la que el cerebro comprende y responde a la información. 

Reconocer los cambios cognitivos en la EP 

Muchas personas con Parkinson pueden experimentar cierto grado de alteraciones del pensamiento. Estos cambios suelen progresar gradualmente junto con los síntomas motores. El deterioro cognitivo leve (DCL o MCI, por sus siglas en inglés) describe alteraciones de la memoria o del pensamiento que no afectan la vida cotidiana. Las personas con la enfermedad de Parkinson de inicio temprano —aquellas que desarrollan síntomas antes de los 50 años— suelen experimentar cambios cognitivos más leves y lentos relacionados con la EP.  

En algunas personas con Parkinson, el cambio cognitivo progresivo puede conducir a la demencia de la EP (DEP), un deterioro más grave del pensamiento. A veces, la persona se da cuenta de que su memoria está fallando, pero otras veces son las personas más cercanas quienes reconocen los signos. El deterioro cognitivo en la EP puede afectar:  

  • La realización de tareas, como organizar medicamentos o utilizar un control remoto.   

  • Las habilidades lingüísticas y de búsqueda de palabras, que afectan la capacidad de seguir instrucciones o participar en conversaciones. 

  • La memoria, que hace que la persona repita preguntas, olvide información importante o tenga problemas para aprender información nueva. 

  • El juicio, que lleva a que la persona ignore riesgos o tome malas decisiones. 

  • La orientación de tiempo y lugar; una persona con problemas del pensamiento puede perderse, especialmente en lugares conocidos. 

Las dificultades de memoria en la EP vs. la enfermedad de Alzheimer 

Los médicos utilizan la Evaluación Cognitiva de Montreal (MoCA, por sus siglas en inglés) como herramienta de detección de alteraciones del pensamiento. Puede distinguir entre tipos de disfunción de la memoria. 

El deterioro de la memoria relacionado con la EP difiere de la enfermedad de Alzheimer. Una buena parte de la memoria de reconocimiento —la capacidad de recordar cosas que uno se ha encontrado antes— permanece prácticamente intacta para la mayoría de las personas con Parkinson. Las personas con Parkinson pueden tener un poco de dificultad para buscar y recuperar un recuerdo, pero con una pista o tiempo suficiente, pueden recordarlo. Por lo general, una persona con Alzheimer es incapaz de crear o recuperar nuevos recuerdos.  

La demencia por la EP, la demencia con cuerpos de Lewy y la enfermedad de Alzheimer están asociadas a proteínas plegadas anormalmente que forman grumos pegajosos que dañan la salud cerebral. Los cuerpos de Lewy son cúmulos tóxicos de proteína alfa-sinucleína que se acumulan en el cerebro.  

Un fallo de la memoria al principio de la EP o un fallo similar al del Alzheimer podrían indicar que la persona con Parkinson también podría tener Alzheimer.  

Posibles descubrimientos

Una comprensión más profunda del complejo funcionamiento de la EP puede mejorar el tratamiento y la atención. Actualmente, los investigadores pueden ver los cúmulos tóxicos asociados a los problemas de memoria mediante técnicas de imagenología. Los científicos confían en que los avances tecnológicos pronto permitan examinar más de cerca la proteína alfa-sinucleína mal plegada.  

La terapia de infusión de anticuerpos puede eliminar el amiloide del cerebro de las personas con la enfermedad de Alzheimer en fase inicial. La esperanza es que las infusiones ralenticen la progresión de la enfermedad. Las futuras terapias para el Parkinson podrían inhibir el mal plegamiento de la proteína alfa-sinucleína para minimizar la formación de cuerpos de Lewy o, posiblemente, incluso eliminar la alfa-sinucleína anormal.  

Herramientas para mejorar la cognición hoy

Al navegar por las etapas y los síntomas del Parkinson, la búsqueda del bienestar puede tener un profundo impacto.  

1. Muévase.

Los beneficios del ejercicio aeróbico en el Parkinson son poderosos. Ya sea que nade, camine o haga otro ejercicio de intensidad moderada, hacer ejercicio 150 minutos por semana puede mejorar la estabilidad y el equilibrio, disminuir el riesgo de caídas, reducir la depresión y beneficiar directamente la cognición en la EP, mejorando: 

  • La atención 

  • La velocidad de procesamiento 

  • El tiempo de reacción 

  • La función ejecutiva 

  • El lenguaje 

El entrenamiento de resistencia —utilizando el peso corporal, pesas o ligas— también puede ser beneficioso para la cognición, el equilibrio, la marcha y la densidad ósea, al tiempo que reduce el riesgo de fracturas en la EP. El entrenamiento de resistencia también mejora la función ejecutiva y la atención.  

2. Practique la atención plena.

Un estudio de 2004 observó cómo 20 personas con Parkinson de leve a moderado y 10 personas que no tenían la EP realizaban una tarea a medida que se añadían grados de complejidad. 

Los investigadores descubrieron que, mientras que el aumento de la atención requerida contribuía a las alteraciones del desempeño y de la marcha en todos los participantes, las personas con Parkinson se volvían aún más lentas. Practicar la atención plena, centrarse en una sola cosa a la vez y bloquear las distracciones, puede ayudarle a funcionar de forma óptima con Parkinson. 

3. Siga una dieta nutritiva.

La dieta MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay), una combinación de la dieta mediterránea y DASH (método dietético para detener la hipertensión, por sus siglas en inglés) para retrasar la degeneración neuronal, es una dieta basada en evidencia para la salud neurológica.

Las recomendaciones incluyen comer: 

  • Al menos 3 raciones de cereales integrales al día. 

  • Una ración diaria mínima de una ensalada de hojas verde oscuro y una ración de verduras. 

  • Al menos 30 gramos de frutos secos al día. 

  • Frijoles o legumbres al menos cada dos días. 

  • Bayas (berries) al menos dos veces por semana. 

  • Aves de corral al menos dos veces por semana. 

  • Pescado al menos una vez a la semana. 

Y limitar:   

  • Mantequilla o margarina a no más de una cucharada sopera al día (utilice en su lugar aceite de oliva). 

  • Queso, alimentos fritos o comida rápida a no más de una vez por semana. 

  • Bollería o dulces a menos de cinco veces por semana. 

4. Duerma lo suficiente.

El sueño de calidad desempeña un papel en la creación y recuperación de recuerdos y puede eliminar algunas de las proteínas anormales asociadas a la pérdida de memoria. También ayuda al cuerpo a reflejar los beneficios del ejercicio.  

Los cambios y síntomas cerebrales relacionados con la EP pueden alterar el sueño. Practicar conductas que lo pongan en el estado óptimo para relajarse puede ayudarle a conciliar el sueño y a permanecer dormido. Una rutina de sueño saludable incluye: 

  • Un horario regular para dormir y despertar (intente reservar al menos 8 horas) 

  • Un dormitorio tranquilo y en penumbra 

  • Tiempo de pantalla mínimo 

Hable con su médico acerca de problemas de sueño o inquietudes al respecto. Pueden trabajar en conjunto para encontrar las mejores herramientas para tratar sus síntomas. 

5. Manténgase conectado socialmente.

Encontrar y establecer relaciones sociales saludables beneficia al cerebro y al cuerpo. Busque recursos comunitarios como punto de partida; por ejemplo, clases de ejercicio, actividades artísticas, grupos de apoyo u oportunidades de voluntariado. Las visitas a domicilio, las llamadas telefónicas o los programas en línea pueden beneficiar a quienes tienen dificultades para salir. 

El aislamiento social y la soledad pueden ser peligrosos.  

  • El aislamiento social se asocia a un aumento de 50% del riesgo de demencia y aumenta significativamente el riesgo de muerte prematura, a niveles de los riesgos del tabaquismo, la obesidad y la inactividad física.  

  • Las investigaciones demuestran que el aislamiento aumenta el riesgo de cardiopatías y accidentes cerebrovasculares en torno a un 30%. 

La soledad puede aumentar la ansiedad, la depresión, la confusión, las delusiones, los problemas de memoria y comunicación y puede afectar la capacidad para resolver problemas. El aislamiento también aumenta la tensión del cuidador, que puede llevar al agotamiento.  

6. Explore el tratamiento.

Su médico puede recomendarle que trabaje con un neuropsicólogo o un terapeuta del habla y el lenguaje especialmente preparados, que pueden ofrecerle formas de compensar los problemas de memoria o pensamiento. 

Algunos medicamentos recetados también pueden mejorar los síntomas de la demencia por la EP. Los inhibidores de la acetilcolinesterasa potencian la acetilcolina (una sustancia química importante para la memoria entre otras cosas) en el cerebro. Entre ellos se encuentran la rivastigmina (el único medicamento para la PEP aprobado por la FDA), el donepezilo y la galantamina. 

La memantina es un medicamento que protege al cerebro de los niveles excesivos de una sustancia química llamada glutamato. A veces se utiliza en combinación con inhibidores de la acetilcolinesterasa.  

Explore otros recursos

Back to Top